Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Prescient Therapeutics

Prescient Therapeutics?uq=UG6efJS6
1986 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
PTX STOCK SYMBOL
$0.06 SHARE PRICE (As of Friday Closing)
Description

Provider of clinical-stage oncology treatment. The company specializes in the development of novel immune therapeutic products based on Co-X-Gene and fowlpox virus delivery technologies for the treatment of chronic infectious diseases and cancer.

Formerly Known As
Virax Holdings Limited
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
ASX
Primary Office
  • Level 2 Riverside Quay,
  • 1 Southbank Boulevard,
  • Southbank, Victoria 3003
  • Australia

+61 (03) 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Prescient Therapeutics’s full profile, request a free trial.

Prescient Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$0.04 - $0.11 $13.7M $0.06 231K 212M

Prescient Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2018
30-Jun-2018
FY 2017
30-Jun-2017
FY 2016
30-Jun-2016
Enterprise Value 13,067 13,067 2,551 5,478
Revenue 8
EBITDA (2,088) (2,088) (2,060) (1,278)
Net Income (1,994) (1,994) (1,935) (1,278)
Total Assets 7,339 7,339 9,398 10,332
Total Debt 41 41 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Prescient Therapeutics Executive Team (2)

Name Title Board
Seat
Contact
Info
Steven Yatomi-Clarke Chief Executive Officer & Managing Director
Terrence Chew MD Chief Medical Officer